Literature DB >> 20388777

Signal transducers and activators of transcription-3 binding to the fibroblast growth factor receptor is activated by receptor amplification.

Anna A Dudka1, Steve M M Sweet, John K Heath.   

Abstract

Fibroblast growth factor receptors (FGFR) are cell surface tyrosine kinases that function in cell proliferation and differentiation. Aberrant FGFR signaling occurs in diverse cancers due to gene amplification, but the associated oncogenic mechanisms are poorly understood. Using a proteomics approach, we identified signal transducers and activators of transcription-3 (STAT3) as a receptor-binding partner that is mediated by Tyr(677) phosphorylation on FGFR. Binding to activated FGFR was essential for subsequent tyrosine phosphorylation and nuclear translocation of STAT3, along with activation of its downstream target genes. Tyrosine phosphorylation of STAT3 was also dependent on concomitant FGFR-dependent activity of SRC and JAK kinases. Lastly, tyrosine (but not serine) phosphorylation of STAT3 required amplified FGFR protein expression, generated either by enforced overexpression or as associated with gene amplification in cancer cells. Our findings show that amplified FGFR expression engages the STAT3 pathway, and they suggest therapeutic strategies to attack FGFR-overexpressing cancers. (c)2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20388777      PMCID: PMC2887080          DOI: 10.1158/0008-5472.CAN-09-3033

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  Real time analysis of STAT3 nucleocytoplasmic shuttling.

Authors:  Albert L Pranada; Silke Metz; Andreas Herrmann; Peter C Heinrich; Gerhard Müller-Newen
Journal:  J Biol Chem       Date:  2003-12-29       Impact factor: 5.157

2.  Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation.

Authors:  Z Wen; Z Zhong; J E Darnell
Journal:  Cell       Date:  1995-07-28       Impact factor: 41.582

3.  Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells.

Authors:  Linda B Mora; Ralf Buettner; John Seigne; Jose Diaz; Nazeel Ahmad; Roy Garcia; Tammy Bowman; Robert Falcone; Rita Fairclough; Alan Cantor; Carlos Muro-Cacho; Sandy Livingston; James Karras; Julio Pow-Sang; Richard Jove
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

4.  Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism.

Authors:  W C Su; M Kitagawa; N Xue; B Xie; S Garofalo; J Cho; C Deng; W A Horton; X Y Fu
Journal:  Nature       Date:  1997-03-20       Impact factor: 49.962

5.  STAT5b, a Mediator of Synergism between c-Src and the Epidermal Growth Factor Receptor.

Authors:  Michael T Kloth; Kristen K Laughlin; Jacqueline S Biscardi; Julie L Boerner; Sarah J Parsons; Corinne M Silva
Journal:  J Biol Chem       Date:  2002-11-11       Impact factor: 5.157

6.  Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein.

Authors:  C L Yu; D J Meyer; G S Campbell; A C Larner; C Carter-Su; J Schwartz; R Jove
Journal:  Science       Date:  1995-07-07       Impact factor: 47.728

7.  Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins.

Authors:  Magdalena Koziczak; Thomas Holbro; Nancy E Hynes
Journal:  Oncogene       Date:  2004-04-29       Impact factor: 9.867

8.  Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias.

Authors:  L Legeai-Mallet; C Benoist-Lasselin; A Munnich; J Bonaventure
Journal:  Bone       Date:  2004-01       Impact factor: 4.398

9.  Structural requirements for signal transducer and activator of transcription 3 binding to phosphotyrosine ligands containing the YXXQ motif.

Authors:  Huang Shao; Xuejun Xu; Mary-Ann A Mastrangelo; Naijie Jing; Richard G Cook; Glen B Legge; David J Tweardy
Journal:  J Biol Chem       Date:  2004-02-13       Impact factor: 5.157

10.  Association of fibroblast growth factor receptor-1 with c-Src correlates with association between c-Src and cortactin.

Authors:  X Zhan; C Plourde; X Hu; R Friesel; T Maciag
Journal:  J Biol Chem       Date:  1994-08-12       Impact factor: 5.157

View more
  38 in total

1.  Signal transducer and activator of transcription 3 and 5 regulate system Xc- and redox balance in human breast cancer cells.

Authors:  Katja Linher-Melville; Sina Haftchenary; Patrick Gunning; Gurmit Singh
Journal:  Mol Cell Biochem       Date:  2015-04-21       Impact factor: 3.396

2.  SH2B1β interacts with STAT3 and enhances fibroblast growth factor 1-induced gene expression during neuronal differentiation.

Authors:  Yu-Jung Chang; Kuan-Wei Chen; Ching-Jen Chen; Ming-Hsing Lin; Yuh-Ju Sun; Jia-Lin Lee; Ing-Ming Chiu; Linyi Chen
Journal:  Mol Cell Biol       Date:  2014-01-06       Impact factor: 4.272

3.  MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines.

Authors:  A Vultur; J Villanueva; C Krepler; G Rajan; Q Chen; M Xiao; L Li; P A Gimotty; M Wilson; J Hayden; F Keeney; K L Nathanson; M Herlyn
Journal:  Oncogene       Date:  2013-04-29       Impact factor: 9.867

4.  Essential role of Stat3 in PI3K-induced oncogenic transformation.

Authors:  Jonathan R Hart; Lujian Liao; John R Yates; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-25       Impact factor: 11.205

5.  Activation of the FGFR-STAT3 pathway in breast cancer cells induces a hyaluronan-rich microenvironment that licenses tumor formation.

Authors:  Laura R Bohrer; Pavlina Chuntova; Lindsey K Bade; Thomas C Beadnell; Ronald P Leon; Nicholas J Brady; Yungil Ryu; Jodi E Goldberg; Stephen C Schmechel; Joseph S Koopmeiners; James B McCarthy; Kathryn L Schwertfeger
Journal:  Cancer Res       Date:  2013-11-06       Impact factor: 12.701

Review 6.  Contribution of chaperones to STAT pathway signaling.

Authors:  Claire E Bocchini; Moses M Kasembeli; Soung-Hun Roh; David J Tweardy
Journal:  JAKSTAT       Date:  2014-10-30

Review 7.  Fibroblast Growth Factor 2 as an Antifibrotic: Antagonism of Myofibroblast Differentiation and Suppression of Pro-Fibrotic Gene Expression.

Authors:  David M Dolivo; Sara A Larson; Tanja Dominko
Journal:  Cytokine Growth Factor Rev       Date:  2017-09-23       Impact factor: 7.638

8.  Novel binding partners and differentially regulated phosphorylation sites clarify Eps8 as a multi-functional adaptor.

Authors:  Debbie L Cunningham; Andrew J Creese; Giulio Auciello; Steve M M Sweet; Tulin Tatar; Joshua Z Rappoport; Melissa M Grant; John K Heath
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

9.  A meta-analysis of 120 246 individuals identifies 18 new loci for fibrinogen concentration.

Authors:  Paul S de Vries; Daniel I Chasman; Maria Sabater-Lleal; Ming-Huei Chen; Jennifer E Huffman; Maristella Steri; Weihong Tang; Alexander Teumer; Riccardo E Marioni; Vera Grossmann; Jouke J Hottenga; Stella Trompet; Martina Müller-Nurasyid; Jing Hua Zhao; Jennifer A Brody; Marcus E Kleber; Xiuqing Guo; Jie Jin Wang; Paul L Auer; John R Attia; Lisa R Yanek; Tarunveer S Ahluwalia; Jari Lahti; Cristina Venturini; Toshiko Tanaka; Lawrence F Bielak; Peter K Joshi; Ares Rocanin-Arjo; Ivana Kolcic; Pau Navarro; Lynda M Rose; Christopher Oldmeadow; Helene Riess; Johanna Mazur; Saonli Basu; Anuj Goel; Qiong Yang; Mohsen Ghanbari; Gonneke Willemsen; Ann Rumley; Edoardo Fiorillo; Anton J M de Craen; Anne Grotevendt; Robert Scott; Kent D Taylor; Graciela E Delgado; Jie Yao; Annette Kifley; Charles Kooperberg; Rehan Qayyum; Lorna M Lopez; Tina L Berentzen; Katri Räikkönen; Massimo Mangino; Stefania Bandinelli; Patricia A Peyser; Sarah Wild; David-Alexandre Trégouët; Alan F Wright; Jonathan Marten; Tatijana Zemunik; Alanna C Morrison; Bengt Sennblad; Geoffrey Tofler; Moniek P M de Maat; Eco J C de Geus; Gordon D Lowe; Magdalena Zoledziewska; Naveed Sattar; Harald Binder; Uwe Völker; Melanie Waldenberger; Kay-Tee Khaw; Barbara Mcknight; Jie Huang; Nancy S Jenny; Elizabeth G Holliday; Lihong Qi; Mark G Mcevoy; Diane M Becker; John M Starr; Antti-Pekka Sarin; Pirro G Hysi; Dena G Hernandez; Min A Jhun; Harry Campbell; Anders Hamsten; Fernando Rivadeneira; Wendy L Mcardle; P Eline Slagboom; Tanja Zeller; Wolfgang Koenig; Bruce M Psaty; Talin Haritunians; Jingmin Liu; Aarno Palotie; André G Uitterlinden; David J Stott; Albert Hofman; Oscar H Franco; Ozren Polasek; Igor Rudan; Pierre-Emmanuel Morange; James F Wilson; Sharon L R Kardia; Luigi Ferrucci; Tim D Spector; Johan G Eriksson; Torben Hansen; Ian J Deary; Lewis C Becker; Rodney J Scott; Paul Mitchell; Winfried März; Nick J Wareham; Annette Peters; Andreas Greinacher; Philipp S Wild; J Wouter Jukema; Dorret I Boomsma; Caroline Hayward; Francesco Cucca; Russell Tracy; Hugh Watkins; Alex P Reiner; Aaron R Folsom; Paul M Ridker; Christopher J O'Donnell; Nicholas L Smith; David P Strachan; Abbas Dehghan
Journal:  Hum Mol Genet       Date:  2015-11-10       Impact factor: 6.150

Review 10.  Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling.

Authors:  Harriet R Ferguson; Michael P Smith; Chiara Francavilla
Journal:  Cells       Date:  2021-05-14       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.